Overview

A Phase 3b Randomized, Double-blind, Multi-center Study to Compare the Safety and Efficacy of Omadacycline to Moxifloxacin for Treating Adult Subjects With CABP

Status:
Recruiting

Trial end date:
2025-11-30

Target enrollment:

Participant gender:

Summary

The primary objective of the study is to show that in Chinese adults with CABP, a course of IV/PO treatment with omadacycline has similar clinical efficacy as the with the comparator antibiotic, IV/PO moxifloxacin. The study is designed as a bridging study, to confirm the results of the pivotal global CABP trial in an ethnically different population of Chinese.

Phase:

Phase 3

Details

Lead Sponsor:

Zai Lab (Hong Kong), Ltd.

Treatments:

Moxifloxacin